Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Akanda Corp. (AKAN:NASDAQ), powered by AI.
Akanda Corp. is currently trading at $10.21. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Akanda Corp. on Alpha Lenz.
Akanda Corp.'s P/E ratio is -2.6.
“Akanda Corp. trades at a P/E of -2.6 (undervalued) with modest ROE of -1830.0%. 3Y revenue CAGR of 172.3% highlights clear growth momentum.”
Ask for details →Akanda Corp. is an equity security representing a company that operates in industries related to medical cannabis and wellness solutions. The primary function of Akanda Corp. is to develop, cultivate, process, and distribute cannabis-derived products aimed at both medicinal and therapeutic applications. The company’s offerings typically span a range of cannabis-based products designed to serve the healthcare sector, targeting patients and medical professionals who require regulated and reliable alternatives for treatment. As a newly listed entity in August 2025, Akanda Corp. highlights the ongoing international integration of the cannabis sector into regulated financial markets, reflecting both evolving consumer demand and shifting legal frameworks worldwide. The company's presence adds diversity to the financial market, offering investors exposure to the intersection of healthcare innovation and agricultural technology. By participating in the capital markets, Akanda Corp. supports advancements in cannabis research, promotes product quality standards, and may contribute to shaping regulatory best practices across the global wellness industry.
“Akanda Corp. trades at a P/E of -2.6 (undervalued) with modest ROE of -1830.0%. 3Y revenue CAGR of 172.3% highlights clear growth momentum.”
Ask for details →Akanda Corp. (ticker: AKAN) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 46 employees. Market cap is $11M.
The current price is $10.21 with a P/E ratio of -2.6x and P/B of 2.49x.
ROE is -1830.03% and operating margin is -523.80%. Annual revenue is $836,664.